


CCK antagonist 1

Cat. No.:	HY-162070
CAS No.:	742116-45-6
Molecular Formula:	C ₂₂ H ₂₂ N ₄ O ₂
Molecular Weight:	374.44
Target:	Cholecystokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (333.83 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.6707 mL	13.3533 mL	26.7065 mL
	5 mM	0.5341 mL	2.6707 mL	5.3413 mL
	10 mM	0.2671 mL	1.3353 mL	2.6707 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CCK antagonist 1 (compound 3d) is a CCK antagonist with IC₅₀s of 1.1 μM and 4 μM for CCK1 and CCK2, respectively. CCK antagonist 1 can be used for research of cancer and mental disease^[1].

IC₅₀ & Target

IC₅₀: 1.1 μM (CCK1), 4 μM (CCK2)^[2]

REFERENCES

[1]. Eric Lattmann, et al. Novel ureido - and amido-pyrazolone derivatives. Patent WO2004106306A1.

[2]. Lattmann E, et al. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists. J Pharm Pharmacol. 2006 Mar;58(3):393-401.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA